Pharmafile Logo

Glaucoma in perspective

- PMLiVE

AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer

Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually

- PMLiVE

Sanofi’s Rezurock receives positive CHMP opinion for chronic graft-versus-host disease

Up to 50% of allogeneic haematopoietic stem cell transplant patients develop chronic GVHD

- PMLiVE

McNamara’s Fallacy

Why marketing science is harder than you think

Photo of Tim Wright plus title of talk

MFN Pricing Is Moving Fast – Here’s What Matters

With GENEROUS, GUARD, and GLOBE all released since December, 185 pages of policy will materially impact U.S. drug pricing — and yes, it's a lot to digest. In a new...

Genesis Research Group

- PMLiVE

Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma

Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable

- PMLiVE

Biogen’s litifilimab receives FDA Breakthrough Therapy Designation for lupus

Therapies like topical steroids manage symptoms but there is currently no cure

- PMLiVE

Alzheimer’s disease – the future of diagnosis and treatment in Europe

Recognising symptoms early and acting quickly can make a real difference to the lives of patients

- PMLiVE

Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration

There are more than three million people affected by IBD globally, with a need to improve current treatments

- PMLiVE

Skyhawk Therapeutics’ SKY-0515 shows positive results in Huntington’s disease

Huntington’s disease affects over 40,000 patients in the US and hundreds of thousands globally

- PMLiVE

Clinical trials on dementia: bridging access and innovation

Addressing the significant challenges surrounding the accessibility and availability of clinical trials

- PMLiVE

AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies

Almost three billion people globally are thought to be either overweight or obese

- PMLiVE

Genentech increases investment to $2bn for US manufacturing site

Roche and Genentech have a current commitment of $50bn for US manufacturing

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links